Fluofarma has developed proprietary biosensors which can report on specific molecular events involved in a range of physiopathological processes such as cancer, neurodegenerative disease and aging.
Fluofarma's probes, based on fluorescent fusion proteins, are reporter substrates for specific cellular events. The biosensing proteins are stably expressed in human cell lines and convert a biological response into a fluorescent signal which is measured by flow cytometry or cellular imaging. Hence, fluorescent changes in living cells expressing a specific biosensor are linked to the corresponding, specific biological event.
Cell lines expressing one of Fluofarma’s biosensors enable screening which focuses on a specific biological event. Moreover, our biosensors can help you understand the compound’s mechanism of action.
Roche adopts Fluofarma’s platform
October 19, 2009 – Fluofarma announced today that it entered into
a multi-year agreement with Roche.
Read
More